Trial · NCT02534571
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | number of participants who presents and confirmed endoscopically as recurrent upper gastro-intestinal bleeding | 30 days | ( Further bleeding is defined by failure to control bleeding at index endoscopy, renewed hematemesis, fresh melena with circulatory instability after initial control of bleeding (systolic blood pressure of 90 mmHg or less or pulse rate of 110 per minute or more) and/or a drop in haemoglobin by 2 g/dl and haematocrit by 10% over 24 hours despite adequate transfusion. Further bleeding after initial endoscopic hemostasis requires documentation with immediate endoscopy which finds fresh blood and active bleeding from a previously treated upper GIB source. Patients with further bleeding after initial endoscopic control are considered to have reached an outcome endpoint. |
| Secondary | number of participants who required subsequent endoscopic treatment upon recurrent bleeding | 30 days | number of participants who required subsequent endoscopic treatment upon recurrent bleeding |
| Secondary | number of participants who required subsequent surgical treatment upon recurrent bleeding | 30 days | number of participants who required subsequent surgical treatment upon recurrent bleeding |
| Secondary | number of participants who required further blood transfusion post randomization | 30 days | number of participants who required further blood transfusion post randomization |
| Secondary | Days of hospitalization post randomization | 60 days | Days of hospitalization post randomization |
| Secondary | number of days which participant required caring in Intensive care unit post randomization | 60 days | number of days which participant required caring in Intensive care unit post randomization |
| Secondary | number of participants with adverse events as a Measure of Safety and Tolerability (related or unrelated to endoscopic treatment) | 30 days | number of participants with adverse events as a Measure of Safety and Tolerability (related or unrelated to endoscopic treatment |
| Secondary | number of participants with mortality from all causes within 30 days randomization. | 30 days | number of participants with mortality from all causes within 30 days randomization |
| Secondary | Ease of endoscopic treatment as measured by Visual Analog Scale reported by Endoscopist | 3 days | self reported VAS scale: 0 cm to 10 cm |
| Secondary | procedure time of endoscopic treatment | 3 days | procedure time of endoscopic treatment |
| Secondary | number of participant who need extra assistant to accomplish the endoscopic treatment | 3 days | number of participant who need extra assistant eg advanced endoscopist to accomplish the endoscopic treatment other than the main endoscopist |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02534571/registered